Screening for bladder cancer: Rationale, limitations, whom to target, and perspectives

European Urology

Volumn 63, Issue 6, 2013, Pages 1049-1058

  Larré, Stéphane ^a   Catto, James W F ^b   Cookson, Michael S ^c   Messing, Edward M ^d   Shariat, Shahrokh F ^e   Soloway, Mark S ^f   Svatek, Robert S ^g   Lotan, Yair ^h   Zlotta, Alexandre R ⁱ   Grossman, H Barton ^j  

^a UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c VANDERBILT UNIVERSITY   (United States)

^d UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^e NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

ⁱ MOUNT SINAI HOSPITAL   (Canada)

^j UNIVERSITY OF TEXAS   (United States)

more..

Author keywords

Early detection of cancer bladder neoplasms; Mandatory testing; Mass screening; Review; Urinary bladder neoplasms

Indexed keywords

TUMOR MARKER;

BLADDER CANCER; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; EARLY DIAGNOSIS; FALSE POSITIVE RESULT; FEASIBILITY STUDY; HIGH RISK POPULATION; HUMAN; MANDATORY TESTING; MASS SCREENING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

CARCINOMA, TRANSITIONAL CELL; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MALE; MASS SCREENING; PATIENT SELECTION; URINARY BLADDER NEOPLASMS;

EID: 84876469856     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.12.062     Document Type: Review

References (55)

1. N. Howlader, Noone Am, and M. Krapcho SEER cancer statistics review, 1975-2009 (vintage 2009 populations) 2012 National Cancer Institute Bethesda, MD
2. J. Wilson, and G. Jungers Principles and practice of screening for disease 1968 World Health Organisation Geneva, Switzerland p. 163
3. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
4. E.M. Messing, R. Madeb, and T. Young Long-term outcome of hematuria home screening for bladder cancer in men Cancer 107 2006 2173 2179
5. G.P. Thériault, C.G. Tremblay, and B.G. Armstrong Bladder cancer screening among primary aluminum production workers in Quebec J Occup Med 32 1990 869 872
6. G.D. Friedman, R.A. Hiatt, C.P. Quesenberry Jr., J.V. Selby, and N.S. Weiss Problems in assessing screening experience in observational studies of screening efficacy: example of urinalysis screening for bladder cancer J Med Screen 2 1995 219 223
7. R. Chou, and T. Dana Screening adults for bladder cancer: a review of the evidence for the U.S. preventive services task force Ann Intern Med 153 2010 461 468
8. A.J. Vickers, C. Bennette, and A.S. Kibel Who should be included in a clinical trial of screening for bladder cancer?: A decision analysis of data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Cancer 119 2013 143 149
9. S.C. Skeldon, K. Semotiuk, and M. Aronson Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer Eur Urol 63 2013 379 385
10. N.D. Freedman, D.T. Silverman, A.R. Hollenbeck, A. Schatzkin, and C.C. Abnet Association between smoking and risk of bladder cancer among men and women JAMA 306 2011 737 745
11. M. Kogevinas, A. T Mannetje, and S. Cordier Occupation and bladder cancer among men in Western Europe Cancer Causes Control 14 2003 907 914
12. E. Pira, G. Piolatto, and E. Negri Bladder cancer mortality of workers exposed to aromatic amines: a 58-year follow-up J Natl Cancer Inst 102 2010 1096 1099
13. T. Mackenzie, M.S. Zens, A. Ferrara, A. Schned, and M.R. Karagas Diabetes and risk of bladder cancer: evidence from a case-control study in New England Cancer 117 2011 1552 1556
14. D.M. Parkin, and S.C. Darby 12. Cancers in 2010 attributable to ionising radiation exposure in the UK Br J Cancer 105 Suppl 2 2011 S57 S65
15. D.M. Parkin The global health burden of infection-associated cancers in the year 2002 Int J Cancer 118 2006 3030 3044
16. L.J. Resseguie, F.T. Nobrega, G.M. Farrow, J.W. Timmons, and T.G. Worobec Epidemiology of renal and ureteral cancer in Rochester, Minnesota, 1950-1974, with special reference to clinical and pathologic features Mayo Clin Proc 53 1978 503 510
17. K. Kishi, T. Hirota, K. Matsumoto, T. Kakizoe, T. Murase, and J. Fujita Carcinoma of the bladder: a clinical and pathological analysis of 87 autopsy cases J Urol 125 1981 36 39
18. A. Vaidya, M.S. Soloway, C. Hawke, R. Tiguert, and F. Civantos De novo muscle invasive bladder cancer: is there a change in trend? J Urol 165 2001 47 50 discussion 50
19. E.M. Messing, T.B. Young, and V.B. Hunt Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations Urology 45 1995 387 396 discussion 396-7
20. G.P. Hemstreet III, S. Yin, and Z. Ma Biomarker risk assessment and bladder cancer detection in a cohort exposed to benzidine J Natl Cancer Inst 93 2001 427 436
21. PDQ® bladder, breast, cervix and colorectal cancers screening. National Cancer Institute Web site. http://cancer.gov/cancertopics/pdq/ screening/bladder/HealthProfessional. Accessed 10 July 2012.
22. V.A. Moyer Screening for bladder cancer: U.S. Preventive Services Task Force recommendation statement Ann Intern Med 155 2011 246 251
23. J.P. Britton, A.C. Dowell, P. Whelan, and C.M. Harris A community study of bladder cancer screening by the detection of occult urinary bleeding J Urol 148 1992 788 790
24. M.P. Mayfield, and P. Whelan Bladder tumours detected on screening: results at 7 years Br J Urol 82 1998 825 828
25. M.J. Roobol, C.H. Bangma, S. El Bouazzaoui, C.G. Franken-Raab, and E.C. Zwarthoff Feasibility study of screening for bladder cancer with urinary molecular markers (the BLU-P project) Urol Oncol 28 2010 686 690
26. H. Hedelin, K. Jonsson, K. Salomonsson, and H. Boman Screening for bladder tumours in men aged 60-70 years with a bladder tumour marker (UBC) and dipstick-detected haematuria using both white-light and fluorescence cystoscopy Scand J Urol Nephrol 40 2006 26 30
27. A.R. Zlotta, T. Roumeguere, and C. Kuk Select screening in a specific high-risk population of patients suggests a stage migration toward detection of non-muscle-invasive bladder cancer Eur Urol 59 2011 1026 1031
28. H. Steiner, M. Bergmeister, and I. Verdorfer Early results of bladder-cancer screening in a high-risk population of heavy smokers BJU Int 102 2008 291 296
29. Y. Lotan, K. Elias, and R.S. Svatek Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker J Urol 182 2009 52 57 discussion 58
30. K. Elias, R.S. Svatek, S. Gupta, R. Ho, and Y. Lotan High-risk patients with hematuria are not evaluated according to guideline recommendations Cancer 116 2010 2954 2959
31. X. Wu, J. Lin, and H.B. Grossman Projecting individualized probabilities of developing bladder cancer in white individuals J Clin Oncol 25 2007 4974 4981
32. E.M. Messing, T.B. Young, V.B. Hunt, J.M. Wehbie, and P. Rust Urinary tract cancers found by homescreening with hematuria dipsticks in healthy men over 50 years of age Cancer 64 1989 2361 2367
33. B. Konety, and Y. Lotan Urothelial bladder cancer: biomarkers for detection and screening BJU Int 102 2008 1234 1241
34. J.P. Britton, A.C. Dowell, and P. Whelan Dipstick haematuria and bladder cancer in men over 60: results of a community study BMJ 299 1989 1010 1012
35. E.M. Messing, T.B. Young, and V.B. Hunt Home screening for hematuria: results of a multiclinic study J Urol 148 1992 289 292
36. J.P. Britton, A.C. Dowell, and P. Whelan Dipstick haematuria: its association with smoking and nonsteroidal anti-inflammatory drugs J R Soc Med 83 1990 149 151
37. D. Tilki, M. Burger, and G. Dalbagni Urine markers for detection and surveillance of non-muscle-invasive bladder cancer Eur Urol 60 2011 484 492
38. E. Ward, W. Halperin, and M. Thun Screening workers exposed to 4,4'-methylenebis(2-chloroaniline) for bladder cancer by cystoscopy J Occup Med 32 1990 865 868
39. C. Giberti, F. Gallo, M. Schenone, and A. Genova Early results of urothelial carcinoma screening in a risk population of coke workers: urothelial carcinoma among coke workers Biomed Environ Sci 23 2010 300 304
40. H.I. Chen, S.H. Liou, C.H. Loh, S.N. Uang, Y.C. Yu, and T.S. Shih Bladder cancer screening and monitoring of 4,4'-methylenebis(2-chloroaniline) exposure among workers in Taiwan Urology 66 2005 305 310
41. M.F. Botteman, C.L. Pashos, A. Redaelli, B. Laskin, and R. Hauser The health economics of bladder cancer: a comprehensive review of the published literature Pharmacoeconomics 21 2003 1315 1330
42. Y. Lotan, R.S. Svatek, and A.I. Sagalowsky Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis Cancer 107 2006 982 990
43. R.S. Svatek, A.I. Sagalowsky, and Y. Lotan Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis Urol Oncol 24 2006 338 343
44. H.B. Grossman, E. Messing, and M. Soloway Detection of bladder cancer using a point-of-care proteomic assay JAMA 293 2005 810 816
45. P.J. Kokorowski, J.C. Routh, J.G. Borer, C.R. Estrada, S.B. Bauer, and C.P. Nelson Screening for malignancy after augmentation cystoplasty in children with spina bifida: a decision analysis J Urol 186 2011 1437 1443
46. M. Mcnaughton-Collins, F.J. Fowler Jr., and J.F. Caubet Psychological effects of a suspicious prostate cancer screening test followed by a benign biopsy result Am J Med 117 2004 719 725
47. L.E. Moore, D.R. Baris, and J.D. Figueroa GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: results from the New England bladder cancer study and NAT2 meta-analysis Carcinogenesis 32 2011 182 189
48. N. Rothman, M. Garcia-Closas, and N. Chatterjee A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci Nat Genet 42 2010 978 984
49. S. Larré, P. Camparo, and E. Comperat Diagnostic, staging, and grading of urothelial carcinomas from urine: performance of BCA-1, a mini-array comparative genomic hybridisation-based test Eur Urol 59 2011 250 257
50. J.W. Catto, S. Miah, and H.C. Owen Distinct microRNA alterations characterize high- and low-grade bladder cancer Cancer Res 69 2009 8472 8481
51. G. Sjodahl, M. Lauss, and K. Lovgren A molecular taxonomy for urothelial carcinoma Clin Cancer Res 18 2012 3377 3386
52. M. Davies Final diagnoses after urinary screening of apparently normal workmen Proc R Soc Med 63 1970 242
53. B. Pesch, M. Nasterlack, and F. Eberle The role of haematuria in bladder cancer screening among men with former occupational exposure to aromatic amines BJU Int 108 2011 546 552
54. J.H. Crosby, W.C. Allsbrook Jr., and L.G. Koss Cytologic detection of urothelial cancer and other abnormalities in a cohort of workers exposed to aromatic amines Acta Cytol 35 1991 263 268
55. G.M. Marsh, and L.D. Cassidy The Drake Health Registry Study: findings from fifteen years of continuous bladder cancer screening Am J Ind Med 43 2003 142 148